- Home
- MLCO vs TARS Comparison
MLCO vs TARS Comparison
Compare MLCO & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLCO | TARS |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MLCO | TARS |
|---|---|---|
| Price | $5.49 | $64.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $10.10 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.8M | 497.0K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $5.61 | $55.67 |
| Revenue Next Year | $4.00 | $30.64 |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $4.55 | $38.51 |
| 52 Week High | $10.15 | $85.25 |
Technical Indicators
Market Signals| Indicator | MLCO | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 37.38 |
| Support Level | $5.22 | $61.11 |
| Resistance Level | $6.54 | $67.70 |
| Average True Range (ATR) | 0.16 | 2.45 |
| MACD | 0.01 | -0.98 |
| Stochastic Oscillator | 8.86 | 6.48 |
Price Performance
Historical ComparisonAbout MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.